TPST Tempest Therapeutics, Inc.

Tempest Therapeutics is a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases where current therapies do not exist or are insufficient. Seeks to create distinct and transformative treatments where there is a significant unmet medical need.

$8.29
As of 12/06/2021     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  06/24/2021
Outstanding shares:  6,910,324
Average volume:  9,844
Market cap:   $57,355,689
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    87978U108
ISIN:        US87978U1088
Sedol:      
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   1.30
PS ratio:   0.00
Return on equity:   -71.02%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy